Eupraxia Pharmaceuticals (NASDAQ:EPRX) Downgraded to “Sell” Rating by Wall Street Zen

Eupraxia Pharmaceuticals (NASDAQ:EPRX) was downgraded by analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a research note issued on Saturday.

A number of other brokerages have also recently weighed in on EPRX. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Eupraxia Pharmaceuticals in a research report on Thursday, January 22nd. Lifesci Capital raised Eupraxia Pharmaceuticals to a “strong-buy” rating in a research note on Thursday, December 11th. Leede Financial raised Eupraxia Pharmaceuticals to a “strong-buy” rating in a research report on Wednesday, October 29th. Cantor Fitzgerald increased their price target on Eupraxia Pharmaceuticals from $11.00 to $19.00 and gave the company an “overweight” rating in a report on Thursday, January 15th. Finally, HC Wainwright restated a “buy” rating and issued a $12.00 price objective on shares of Eupraxia Pharmaceuticals in a research note on Friday, January 9th. Two research analysts have rated the stock with a Strong Buy rating, three have issued a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, the company has a consensus rating of “Buy” and an average price target of $15.50.

Eupraxia Pharmaceuticals Trading Up 4.7%

Eupraxia Pharmaceuticals stock opened at $8.50 on Friday. Eupraxia Pharmaceuticals has a 1-year low of $2.68 and a 1-year high of $9.32. The firm’s fifty day simple moving average is $8.02 and its 200-day simple moving average is $6.54. The company has a market capitalization of $305.66 million, a P/E ratio of -9.77 and a beta of 1.20.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of EPRX. XTX Topco Ltd bought a new stake in shares of Eupraxia Pharmaceuticals in the fourth quarter valued at approximately $122,000. Ikarian Capital LLC bought a new stake in Eupraxia Pharmaceuticals in the 4th quarter valued at $4,606,000. Squadron Capital Management LLC bought a new stake in Eupraxia Pharmaceuticals in the 4th quarter valued at $3,775,000. SummitTX Capital L.P. acquired a new stake in Eupraxia Pharmaceuticals in the 4th quarter worth $1,328,000. Finally, Quadrature Capital Ltd bought a new position in shares of Eupraxia Pharmaceuticals during the 4th quarter worth about $326,000.

About Eupraxia Pharmaceuticals

Eupraxia Pharmaceuticals, Inc (NASDAQ: EPRX) is a clinical-stage biotechnology company dedicated to the discovery and development of novel therapies for autoimmune and inflammatory diseases. The company’s core strategy centers on selectively expanding regulatory T cells (Tregs)—immune cells responsible for maintaining self-tolerance and limiting pathological inflammation—through its proprietary platform. Its lead therapeutic candidate is currently in Phase 1 clinical development in patients with systemic lupus erythematosus.

Based in Seattle, Washington, Eupraxia Pharmaceuticals conducts research and development activities across North America, collaborating with academic institutions and contract research organizations to advance its pipeline.